Clarivate

DECEMBER 6, 2022

healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst. Pillo, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

PM360

SEPTEMBER 15, 2022

But battling information asymmetry is one of the best ways to address the ongoing inequities in our healthcare system. But to shift the industry’s approach to healthcare, all stakeholders must move the efforts, attention, and education necessary to find a common ground and ensure that the patients’ interests are always driving development.

Patients 98

Patients Healthcare Healthcare Marketing 98

Clarivate

AUGUST 7, 2023

In the coming weeks we will fully transition Dialog Solutions to the Clarivate identity, folding the Dialog offerings into our Life Sciences & Healthcare portfolio of solutions. This will be achieved via highly specialized analytics and unique expert insights.

Specialization 52

Specialization Management Healthcare Healthcare 52

Clarivate

APRIL 19, 2024

Liver cancer and focal liver lesions Liver cancer ranks as the third-leading cause of cancer-related deaths worldwide. [5] 4] Such insights can also help optimize medical workflows, and ultimately reduce healthcare utilisation. [9] LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems.

Medical 59

Medical Patients Specialization Healthcare 59

PM360

JUNE 30, 2022

It includes companies Vynamic, Research Partnership, Putnam Associates, and STEM Healthcare. Inizio Medical: By combining complex scientific understanding with creativity, Inizio Medical promises to create compelling content and engage communities across the spectrum of healthcare.

Specialization 97

Specialization Consulting Healthcare Healthcare 97

pharmaphorum

JANUARY 11, 2023

Last year, digital health ventures registered a total of 575 regulatory filings around the world, with the medical diagnostics cluster – diagnostic tools, medical imaging, and omics-related analyses – leading the charge with 12% of the total. Roche tops biopharma partnering podium.

Biopharma 72

Biopharma Specialization Physicians Healthcare 72

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Rishi Kadiwar.

Patients 59

Patients Pharma Education Media 59

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. The path to real zero.

Manufacturing 76

Manufacturing Pharmaceutical Healthcare Healthcare 76

Medgadget

MARCH 2, 2023

This leads to substantial damage to healthy tissues and too often results in poor outcomes. Special software that takes DICOM images from CT scanners and creates a treatment plan, defines the distribution of the Alpha DaRT sources within the tumor. which are currently recruiting patients.

Manufacturing 83

Manufacturing Leads Patients Medicine 83

Pharmaceutical Technology

APRIL 24, 2023

The rise of biologics In the lead-up to the 2020 boom, Swiss drugmaker Roche spent some $11 billion on biotechnology research and development in 2018. Because biologics work with live cells, manufacturing them is difficult, and highly specialized facilities and infrastructure are needed. Biopharma outsourcing has rapidly developed.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52

Pharmaceutical Technology

JANUARY 25, 2023

Although expert opinions differ on the future of special purpose acquisition companies (SPACs), some companies are continuing to explore their use. In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp.

Marketing 69

Marketing Biopharma Pharma Competition 69